NantHealth – Consensus Indicates Potential 43.7% Upside

Broker Ratings

NantHealth found using ticker (NH) now have 2 analysts in total covering the stock. The consensus rating is ‘None’. The range between the high target price and low target price is between 4 and 3.5 with a mean TP of 3.75. Given that the stocks previous close was at 2.61 this would imply there is a potential upside of 43.7%. The 50 day MA is 3.22 and the 200 moving average now moves to 3.16. The market capitalisation for the company is $291m. You can visit the company’s website by visiting:

NantHealth, together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform’s comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth is as a subsidiary of NantWorks, LLC.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index